Latest News and Press Releases

The Phase III study is expected to commence in the U.S. by the end of this month RHB-105 is a new and proprietary combination therapy in an oral capsule for the treatment of H. pylori...

The retrospective study, presented at the 2013 American College of Gastroenterology (ACG) Annual Scientific Meeting, demonstrated strong results with a high remission rate of 80% RedHill's...

Following the positive results from two supportive pharmacokinetic (PK) studies, the Company plans to file a new drug application (NDA) in the first quarter of 2014 and is seeking a pre-NDA...

RedHill has initiated the patient screening process in a randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the safety and efficacy of RHB-104 for treatment of...

TEL-AVIV, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...

The Company is assessing the possibility of a Phase IIa proof of concept study in systemic lupus erythematosus as a next step RedHill expects to commence a Phase III study with RHB-104 for...

TEL-AVIV, Israel, Sept. 3, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...

The Company recently held successful Scientific Advice Meetings with the UK and Swedish pharmaceutical regulatory agencies to discuss its European Phase III strategy with RHB-104 for Crohn's...

The planned phase IIa, proof of concept, clinical study will assess the efficacy and safety of RHB-104 in patients suffering from rheumatoid arthritis (RA) RA is one of the most common...

RedHill continues advanced preparations for the Phase III study with RHB-104 (Crohn's) and Phase II/III study with RHB-105 (H. pylori) Key Highlights include: FDA acceptance of RHB-103...